COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03834038
Recruitment Status : Active, not recruiting
First Posted : February 7, 2019
Last Update Posted : May 17, 2019
Information provided by (Responsible Party):
Vancouver Island Health Authority

Brief Summary:
The primary goal is to study participants with recurrent C. difficile infection (CDI) treated with lyophilized fecal microbiota transplantation (FMT). The safety, clinical response and relapse rate in patients will be assessed.

Condition or disease Intervention/treatment Phase
Clostridium Difficile Infection Drug: Lyophilized Fecal Microbiota Transplantation Not Applicable

Detailed Description:
Recurrence of CDI following a course of standard antibiotic therapy is high, especially in the elderly patients over 65 years of age, in hospitalized and in the immunocompromised patients. As CDI is characterized by intestinal dysbiosis. Fecal Microbiology Transplantation (FMT) has been investigated as alternative treatment for CDI and has been determined to be effective and safe. One of the major challenges of offering FMT is the availability of suitable donors. A donor may no longer be able to continue to donate for a number of reasons and this may lead to temporary interruption of FMT in centers which offer the program. In order to continue to offer FMT whenever needed, we will investigate the efficacy of lyophilized FMT. The lyophilization (freeze-drying) process works by dehydrating a frozen donor stool sample to complete dryness, using controlled temperature and pressure gradients. This lyophilized process results in a powdered form of the sample. Studies have shown that lyophilized donor stool samples have similar microbial compositions as the same fresh sample.The technique of freeze drying has been used for decades for the industrial storage of microbes and has been used. Preliminary study of lyophilized stool for FMT has been performed in dogs. Preliminary efficacy data in dogs with inflammatory bowel disease suggest equal efficacy as compared to fresh stool, although controlled study has yet to be performed. Should the lyophilized FMT (L-FMT) demonstrate to be equally or more effective than frozen FMT, there would be significant advantages. As with frozen FMT, lyophilized FMT will allow patients to receive FMT immediately as it can take up to two weeks for a donor's screening laboratory testing results to be available. Lyophilized FMT will also be more cost effective as less number of donors will need to be screened given the prolonged shelf life of lyophilized FMT which can be kept at above the freezing temperature. 9 This will also allow wider distribution and accessibility especially to the regions with limited capacity to manufacture FMT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. Difficile Infection
Actual Study Start Date : February 18, 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Arm Intervention/treatment
Experimental: Open Label Lyophilized Fecal Microbiota Transplantation
Eligible participants with history of recurrent or refractory CDI
Drug: Lyophilized Fecal Microbiota Transplantation
Lyophilized FMT

Primary Outcome Measures :
  1. Treatment of CDI [ Time Frame: 13 weeks from last FMT ]
    Evaluate treatment efficacy determined by no recurrence of CDI-related diarrhea

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 12 years or older.
  • Able to provide informed consent.
  • Willing and able to comply with all the required study procedures.
  • A positive stool test for C. difficile toxin/gene using either PCR or enzyme immunoassay within 3 months of recruitment unless patient taking treatment specifically for CDI for more than 3 months.
  • History of at least ≥ 2 recurrent CDI where recurrence is defined as return of diarrhea consistent with CDI within 8 weeks following CDI symptom resolution for at least 24 hours after a minimum of 10-day course of standard antibiotic therapy for each episode and/or ongoing symptoms consistent with CDI* (defined below) despite at least 7 days of treatment using oral vancomycin at a minimum dose of 250 mg four times daily.

    • Symptoms of CDI include: diarrhea defined as: 3 or more unformed bowel movements in 24 hours for a minimum of 2 days with no other causes for diarrhea

Exclusion Criteria:

  • Planned or actively taking another investigational product
  • CDI symptom-free for 3 or more weeks following completion of CDI treatment
  • Patients with neutropenia with absolute neutrophil count <0.5 x 109/L
  • Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray
  • Active gastroenteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter.
  • Presence of colostomy
  • Unable to tolerate FMT or enema for any reason.
  • Requiring systemic antibiotic therapy for more than 7 days.
  • Actively taking Saccharomyces boulardii or other probiotic; yogurt is allowed
  • Severe underlying disease such that the patient is not expected to survive for at least 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03834038

Layout table for location information
Canada, British Columbia
Vancouver Island Health Authority
Victoria, British Columbia, Canada, V8R 1J8
Sponsors and Collaborators
Vancouver Island Health Authority
Layout table for investigator information
Principal Investigator: Christine Lee, MD Vancouver Island Health Authority
Layout table for additonal information
Responsible Party: Vancouver Island Health Authority Identifier: NCT03834038    
Other Study ID Numbers: CDI.LYO.FMT (C2016-020)
First Posted: February 7, 2019    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Clostridium Infections
Enterocolitis, Pseudomembranous
Gram-Positive Bacterial Infections
Bacterial Infections
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases